$OPGN
OPGEN INC Stock $opgn

$opgn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000182912624005664 Filed on August 19, 2024

Income Statement

Concept	2024 Q2
Revenue	$28.00K
YoY Change	-96.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.594M
YoY Change	-55.54%
% of Gross Profit
Research & Development	$22.96K
YoY Change	-98.35%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.617M
YoY Change	-67.49%
Operating Profit	-$1.547M
YoY Change	-69.99%
Interest Expense	$1.079K
YoY Change	-99.84%
% of Operating Profit
Other Income/Expense, Net	-$29.04K
YoY Change	-95.67%
Pretax Income	-$1.576M
YoY Change	-72.95%
Income Tax
% Of Pretax Income
Net Earnings	-$1.576M
YoY Change	-72.95%
Net Earnings / Revenue	-5629.82%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	1.344M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$168.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$25.40K
Other Receivables
Total Short-Term Assets	$572.8K
YoY Change	-92.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.155M
YoY Change	-69.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$302.3K
YoY Change	-39.17%
Total Long-Term Assets	$2.297M
YoY Change	-84.9%
TOTAL ASSETS
Total Short-Term Assets	$572.8K
Total Long-Term Assets	$2.297M
Total Assets	$2.870M
YoY Change	-87.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$128.4K
YoY Change	-34.26%
Accrued Expenses	$565.3K
YoY Change	-45.81%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$11.10M
YoY Change	20.76%
Total Short-Term Liabilities	$12.60M
YoY Change	1.48%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.60M
Total Long-Term Liabilities
Total Liabilities	$14.54M
YoY Change	-6.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$306.8M
YoY Change	7.87%
Common Stock	$13.49K
YoY Change	-80.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.500M
YoY Change
Total Liabilities & Shareholders Equity	$2.870M
YoY Change	-87.21%

Cashflow Statement

Concept	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.576M
YoY Change	-72.95%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	150658	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37367
	dei	Entity Registrant Name EntityRegistrantName	OPGEN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1614015
	dei	Entity Address Address Line1 EntityAddressAddressLine1	23219 Stringtown Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Clarksburg
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20871
	dei	City Area Code CityAreaCode	240
	dei	Local Phone Number LocalPhoneNumber	813-1260
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	OPGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8355496	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1151823	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	103316	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	324735	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1579874	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2021616	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13443858	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1348974	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1348974	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1282686	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1282686	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	13490	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12827	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	295094492	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	293991529	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306781684	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-305493302	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-75138	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-11668200	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11561584	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2869553	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1882274	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2024Q2	opgn	Cost Of Products Sold CostOfProductsSold	-41600	usd
CY2023Q2	opgn	Cost Of Products Sold CostOfProductsSold	714392	usd
	opgn	Cost Of Products Sold CostOfProductsSold	31636	usd
	opgn	Cost Of Products Sold CostOfProductsSold	1306770	usd
CY2023Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	204102	usd
	opgn	Cost Of Products Sold CostOfProductsSold	31636	usd
CY2023Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	204102	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1575	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1388792	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1575	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	332408	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22964	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1388792	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48820	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3201624	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1568619	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2425007	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3252770	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4848960	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25327	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1160200	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48820	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3201624	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1568619	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2425007	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3252770	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4848960	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25327	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1160200	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	153973	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	153973	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2186287	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	1575310	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	5892493	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3488774	usd
	us-gaap	Costs And Expenses CostsAndExpenses	11876049	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2186287	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	5892493	usd
	us-gaap	Costs And Expenses CostsAndExpenses	3488774	usd
	us-gaap	Costs And Expenses CostsAndExpenses	11876049	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1547310	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5156356	usd
CY2023Q2	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	31215	usd
	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	150668	usd
	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	61323	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1079	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2023Q4	opgn	Indemnification Assets IndemnificationAssets		usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q4	opgn	Shortterm Insurance Financing ShorttermInsuranceFinancing		usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2024Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating		usd
CY2024Q2	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment		usd
CY2023Q2	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment		usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment		usd
CY2024Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2023Q2	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty		usd
	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023Q1	opgn	Stock Issued During Period Share Cancellation Value StockIssuedDuringPeriodShareCancellationValue		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2024Q1	opgn	Reclassification Of Preferred Stock Par Value To Additional Paidin Capital ReclassificationOfPreferredStockParValueToAdditionalPaidinCapital		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2024Q2	opgn	Share Issuance Related To Reverse Stock Split ShareIssuanceRelatedToReverseStockSplit		usd
CY2024Q2	opgn	Share Cancellation Related To Reverse Stock Split ShareCancellationRelatedToReverseStockSplit		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	opgn	Cash Bonus Taken In Form Of Stock Compensation CashBonusTakenInFormOfStockCompensation		usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment		usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1547310	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5156356	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3292625	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10226468	usd
CY2023Q2	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	31215	usd
	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	150668	usd
	opgn	Interest And Other Income Net InterestAndOtherIncomeNet	61323	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	111149	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	135476	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25926	usd
CY2023Q4	opgn	Eib Loan Guaranty EibLoanGuaranty	10873867	usd
CY2024Q2	opgn	Shortterm Insurance Financing ShorttermInsuranceFinancing	270833	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	147943	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11422242	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1938571	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2021616	usd
CY2024Q2	us-gaap	Liabilities Liabilities	14537753	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13443858	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1348974	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1348974	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1282686	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	13490	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12827	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	295094492	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	293991529	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306781684	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-305493302	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-75138	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-11668200	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11561584	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2869553	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1882274	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2024Q2	opgn	Cost Of Products Sold CostOfProductsSold	-41600	usd
CY2023Q2	opgn	Cost Of Products Sold CostOfProductsSold	714392	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1079	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	684498	usd
	us-gaap	Interest Expense InterestExpense	1301796	usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment	2079575	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	184	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	684498	usd
	us-gaap	Interest Expense InterestExpense	1079	usd
	us-gaap	Interest Expense InterestExpense	1301796	usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment	2079575	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	184	usd
	opgn	Change In Fair Value Of Eib Loan ChangeInFairValueOfEibLoan		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants		usd
	opgn	Proceeds From Shortterm Insurance Financing ProceedsFromShorttermInsuranceFinancing		usd
	opgn	Payments On Shortterm Insurance Financing PaymentsOnShorttermInsuranceFinancing		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	opgn	Rightofuse Assets Acquired Through Operating Leases RightofuseAssetsAcquiredThroughOperatingLeases		usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves		usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves		usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves		usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves		usd
CY2024Q2	us-gaap	Inventory Net InventoryNet		usd
CY2023Q4	us-gaap	Inventory Net InventoryNet		usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent		pure
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability		usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability		usd
	opgn	Operating Leases OperatingLeases		usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1155216	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	138	usd
CY2024Q2	opgn	Indemnification Assets IndemnificationAssets	839302	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	302262	usd
CY2023Q4	us-gaap	Assets Assets	1882274	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	111149	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	374939	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	127601	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	135476	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25926	usd
CY2024Q2	opgn	Eib Loan Guaranty EibLoanGuaranty	11099253	usd
CY2023Q4	opgn	Eib Loan Guaranty EibLoanGuaranty	10873867	usd
CY2024Q2	opgn	Shortterm Insurance Financing ShorttermInsuranceFinancing	270833	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	280	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	160480	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	147943	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12599182	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11422242	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-60401	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	42717	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	55411	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	465	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-152396	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	42717	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	55411	usd
CY2024Q2	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty	178802	usd
	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty	225386	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29039	usd
CY2024Q2	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty	178802	usd
	opgn	Change In Fair Value Of Eib Loan Guaranty ChangeInFairValueOfEibLoanGuaranty	225386	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29039	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-670967	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1576349	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1576349	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5827323	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2004243	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1337458	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1576349	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1288382	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11563926	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5827323	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1288382	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11563926	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1576349	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5827323	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1288382	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11563926	usd
CY2024Q2	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-1.18
CY2023Q2	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-9.33
	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.98
	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-21.32
CY2024Q2	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	1340285	shares
CY2023Q2	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	624633	shares
	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	1312544	shares
	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	542455	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5827323	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1288382	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11563926	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-113704	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39363	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1576349	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5941027	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11524563	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7575548	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	211122	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	153067	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5736603	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	156529	usd
CY2023Q2	opgn	Cash Bonus Taken In Form Of Stocks Compensation CashBonusTakenInFormOfStocksCompensation	283554	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-113704	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5827323	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6859890	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11561584	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	188237	usd
CY2024Q1	opgn	Offering Of Preferred Stock And Warrants Net Of Issuance Costs OfferingOfPreferredStockAndWarrantsNetOfIssuanceCosts	200000	usd
CY2024Q1	opgn	Elimination Of Translation Adjustments Of Previously Dissolved Subsidiaries EliminationOfTranslationAdjustmentsOfPreviouslyDissolvedSubsidiaries	75138	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	287967	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10810242	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	368391	usd
CY2024Q2	opgn	Offering Of Preferred Stock And Warrants Net Of Issuance Costs OfferingOfPreferredStockAndWarrantsNetOfIssuanceCosts	350000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-11668200	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1288382	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11563926	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85195	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1288382	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11563926	usd
CY2024Q2	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-1.18
CY2023Q2	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-9.33
	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.98
	opgn	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-21.32
CY2024Q2	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	1340285	shares
CY2023Q2	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	624633	shares
	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	1312544	shares
	opgn	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	542455	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5827323	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1288382	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11563926	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-113704	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1576349	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5941027	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1288382	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11524563	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7575548	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	211122	usd
CY2023Q1	opgn	Offering Of Common Stock And Warrants Net Of Issuance Costs OfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	6974050	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	153067	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5736603	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9177184	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	156529	usd
CY2023Q2	opgn	Cash Bonus Taken In Form Of Stocks Compensation CashBonusTakenInFormOfStocksCompensation	283554	usd
CY2023Q2	opgn	Offering Of Common Stock And Warrants Net Of Issuance Costs OfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	3183650	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-113704	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5827323	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6859890	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11561584	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	188237	usd
CY2024Q1	opgn	Offering Of Preferred Stock And Warrants Net Of Issuance Costs OfferingOfPreferredStockAndWarrantsNetOfIssuanceCosts	200000	usd
CY2024Q1	opgn	Elimination Of Translation Adjustments Of Previously Dissolved Subsidiaries EliminationOfTranslationAdjustmentsOfPreviouslyDissolvedSubsidiaries	75138	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	287967	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10810242	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	368391	usd
CY2024Q2	opgn	Offering Of Preferred Stock And Warrants Net Of Issuance Costs OfferingOfPreferredStockAndWarrantsNetOfIssuanceCosts	350000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576349	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-11668200	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1288382	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11563926	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85195	usd
	us-gaap	Accretion Expense AccretionExpense	1017312	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	556628	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	367651	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-54830	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	367048	usd
	opgn	Cash Bonus Taken In Form Of Stock Compensation CashBonusTakenInFormOfStockCompensation	283554	usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment	2079575	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-75138	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	721887	usd
	us-gaap	Accretion Expense AccretionExpense	1017312	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	556628	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	367651	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-54830	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	367048	usd
	opgn	Cash Bonus Taken In Form Of Stock Compensation CashBonusTakenInFormOfStockCompensation	283554	usd
	opgn	Gain On Impairment Adjustment GainOnImpairmentAdjustment	2079575	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-75138	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-55411	usd
	opgn	Change In Fair Value Of Eib Loan ChangeInFairValueOfEibLoan	225386	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-77914	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	97027	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-54830	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9120	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54521	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	82510	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	17220	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-228118	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	606661	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-319726	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25926	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-116820	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1804262	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9715206	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	697761	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10157700	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	550000	usd
	opgn	Proceeds From Shortterm Insurance Financing ProceedsFromShorttermInsuranceFinancing	300926	usd
	opgn	Payments On Shortterm Insurance Financing PaymentsOnShorttermInsuranceFinancing	30093	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	280	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	820553	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6248090	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36712	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-983709	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4201589	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1454085	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7935659	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470376	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3734070	usd
	us-gaap	Interest Paid Net InterestPaidNet	1079	usd
	us-gaap	Interest Paid Net InterestPaidNet	1421418	usd
	opgn	Rightofuse Assets Acquired Through Operating Leases RightofuseAssetsAcquiredThroughOperatingLeases	801321	usd
CY2024Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1089274	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.785
CY2023Q4	opgn	Additional Consideration Required AdditionalConsiderationRequired	0.25
CY2023Q4	opgn	Shares Exercised SharesExercised	200000	shares
CY2023Q4	us-gaap	Investments Investments	250000	usd
CY2023Q4	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	1000000.0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-55411	usd
	opgn	Change In Fair Value Of Eib Loan ChangeInFairValueOfEibLoan	225386	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-77914	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	97027	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-54830	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9120	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54521	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	82510	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	17220	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-228118	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	606661	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-319726	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25926	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-116820	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1804262	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9715206	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	697761	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-697761	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10157700	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	550000	usd
	opgn	Proceeds From Shortterm Insurance Financing ProceedsFromShorttermInsuranceFinancing	300926	usd
	opgn	Payments On Shortterm Insurance Financing PaymentsOnShorttermInsuranceFinancing	30093	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	820553	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6248090	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36712	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-983709	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4201589	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1454085	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7935659	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470376	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3734070	usd
	us-gaap	Interest Paid Net InterestPaidNet	1421418	usd
	opgn	Rightofuse Assets Acquired Through Operating Leases RightofuseAssetsAcquiredThroughOperatingLeases	801321	usd
CY2024Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1089274	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.785
CY2023Q4	opgn	Additional Consideration Required AdditionalConsiderationRequired	0.25
CY2023Q4	opgn	Shares Exercised SharesExercised	200000	shares
CY2023Q4	us-gaap	Investments Investments	250000	usd
CY2023Q4	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	1000000.0	usd
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	3000000
CY2023Q2	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	1000000
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds Issuance From Warrants NetProceedsIssuanceFromWarrants	3000000.0	usd
CY2023Q4	opgn	Payment Of Additional Consideration Price PaymentOfAdditionalConsiderationPrice	0.25
CY2023Q2	opgn	Number Of Warrants Repriced NumberOfWarrantsRepriced	639691	shares
CY2023Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	7.785
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	opgn	Increase In Fair Value Resulting From Warrant Modification IncreaseInFairValueResultingFromWarrantModification	300000	usd
	opgn	Common Shares Exercised CommonSharesExercised	200000	shares
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-228118	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	606661	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25926	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-116820	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1804262	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9715206	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	697761	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-697761	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10157700	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	550000	usd
	opgn	Proceeds From Shortterm Insurance Financing ProceedsFromShorttermInsuranceFinancing	300926	usd
	opgn	Payments On Shortterm Insurance Financing PaymentsOnShorttermInsuranceFinancing	30093	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	3907928	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	280	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6248090	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-36712	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-983709	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4201589	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1454085	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7935659	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470376	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3734070	usd
	us-gaap	Interest Paid Net InterestPaidNet	1079	usd
	opgn	Rightofuse Assets Acquired Through Operating Leases RightofuseAssetsAcquiredThroughOperatingLeases	801321	usd
CY2024Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1089274	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.785
CY2023Q4	opgn	Additional Consideration Required AdditionalConsiderationRequired	0.25
CY2023Q4	opgn	Shares Exercised SharesExercised	200000	shares
CY2024Q2	opgn	Gross Proceeds From2023 Warrant Inducement GrossProceedsFrom2023WarrantInducement	2057000.000	usd
CY2023Q4	us-gaap	Investments Investments	250000	usd
CY2023Q4	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	1000000.0	usd
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	3000000
CY2023Q2	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	1000000
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds Issuance From Warrants NetProceedsIssuanceFromWarrants	3000000.0	usd
CY2023Q4	opgn	Payment Of Additional Consideration Price PaymentOfAdditionalConsiderationPrice	0.25
CY2023Q2	opgn	Number Of Warrants Repriced NumberOfWarrantsRepriced	639691	shares
CY2023Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	7.785
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	opgn	Increase In Fair Value Resulting From Warrant Modification IncreaseInFairValueResultingFromWarrantModification	300000	usd
	opgn	Common Shares Exercised CommonSharesExercised	200000	shares
CY2024Q2	opgn	Gross Proceeds From2023 Warrant Inducement GrossProceedsFrom2023WarrantInducement	2057000.000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	26.50
CY2023Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	7.785
CY2024Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2500000	usd
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	3000000
CY2023Q2	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	1000000
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds Issuance From Warrants NetProceedsIssuanceFromWarrants	3000000.0	usd
CY2023Q4	opgn	Payment Of Additional Consideration Price PaymentOfAdditionalConsiderationPrice	0.25
CY2023Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	7.785
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	opgn	Increase In Fair Value Resulting From Warrant Modification IncreaseInFairValueResultingFromWarrantModification	300000	usd
	opgn	Common Shares Exercised CommonSharesExercised	200000	shares
CY2024Q2	opgn	Gross Proceeds From2023 Warrant Inducement GrossProceedsFrom2023WarrantInducement	2057000.000	usd
	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	2500	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2500	usd
	opgn	Accumulated Other Comprehensive Loss AccumulatedOtherComprehensiveLoss	75100	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-75138	usd
	opgn	Incremental Loss IncrementalLoss	100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zkLAn0liLiJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zcvvGcZjJrWj">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, property and equipment, lease right-of-use assets, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, and deferred tax assets and liabilities and related valuation allowance. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	opgn	Gross Proceeds From2023 Warrant Inducement GrossProceedsFrom2023WarrantInducement	2057000.000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	26.50
CY2023Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	7.785
CY2024Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2500000	usd
	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	2500	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2500	usd
	opgn	Accumulated Other Comprehensive Loss AccumulatedOtherComprehensiveLoss	75100	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-75138	usd
	opgn	Incremental Loss IncrementalLoss	100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zkLAn0liLiJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zcvvGcZjJrWj">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, property and equipment, lease right-of-use assets, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, and deferred tax assets and liabilities and related valuation allowance. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	2500	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2500	usd
	opgn	Accumulated Other Comprehensive Loss AccumulatedOtherComprehensiveLoss	75100	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-75138	usd
	opgn	Incremental Loss IncrementalLoss	100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zkLAn0liLiJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zcvvGcZjJrWj">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, property and equipment, lease right-of-use assets, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, and deferred tax assets and liabilities and related valuation allowance. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	168114	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3237176	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7440030	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	495629	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	470376	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1454085	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3734070	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7935659	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	168114	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3237176	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7440030	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	496894	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	495629	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	470376	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1454085	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3734070	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7935659	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1225975	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1280805	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	1225975	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	168114	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1151823	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3237176	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7440030	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	302262	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	496894	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	495629	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	470376	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1454085	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3734070	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7935659	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1225975	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1280805	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	1225975	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	1280805	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1280805	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	1225975	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	1280805	usd
CY2024Q2	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1225975	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1280805	usd
CY2024Q2	us-gaap	Other Inventory OtherInventory	1225975	usd
CY2023Q4	us-gaap	Other Inventory OtherInventory	1280805	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q1	opgn	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	849243	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	187540	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	88421	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	222359	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q2	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1225975	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1280805	usd
CY2024Q2	us-gaap	Other Inventory OtherInventory	1225975	usd
CY2023Q4	us-gaap	Other Inventory OtherInventory	1280805	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q1	opgn	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	849243	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	187540	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	88421	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	222359	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q2	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1225975	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	-1280805	usd
CY2024Q2	us-gaap	Other Inventory OtherInventory	1225975	usd
CY2023Q4	us-gaap	Other Inventory OtherInventory	1280805	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q1	opgn	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	849243	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	187540	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	88421	usd
	opgn	Research And Development Expense From Government Grant ResearchAndDevelopmentExpenseFromGovernmentGrant	222359	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	opgn	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	241110447	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	232682072	usd
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	2500000	shares
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	1100000	shares
	opgn	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	241110447	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	232682072	usd
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	2500000	shares
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	1100000	shares
	opgn	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	241110447	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	232682072	usd
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	2500000	shares
	us-gaap	Weighted Average Limited Partnership Units Outstanding Diluted WeightedAverageLimitedPartnershipUnitsOutstandingDiluted	1100000	shares
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2023	us-gaap	Contract With Customer Asset Purchase ContractWithCustomerAssetPurchase	74109	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-144196	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-46048	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25926	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-21096	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	142061	usd
CY2023	us-gaap	Contract With Customer Asset Purchase ContractWithCustomerAssetPurchase	74109	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-144196	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-46048	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25926	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-21096	usd
	opgn	Refunded To Customers In Current Period RefundedToCustomersInCurrentPeriod	-4830	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
CY2024Q2	us-gaap	Revenues Revenues	28000	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
CY2023Q2	us-gaap	Revenues Revenues	736137	usd
	us-gaap	Revenues Revenues	196149	usd
	us-gaap	Revenues Revenues	1649581	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	142061	usd
CY2023	us-gaap	Contract With Customer Asset Purchase ContractWithCustomerAssetPurchase	74109	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-46048	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25926	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-21096	usd
	opgn	Refunded To Customers In Current Period RefundedToCustomersInCurrentPeriod	-4830	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	opgn	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	849243	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
	opgn	Refunded To Customers In Current Period RefundedToCustomersInCurrentPeriod	-4830	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1231874	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	849243	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1230332	usd
	opgn	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	849243	usd
	opgn	Operating Lease Impairment Losses OperatingLeaseImpairmentLosses	0	usd
CY2024Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	11099253	usd
CY2023Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10873867	usd
CY2017Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.04	pure
CY2019Q2	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	5000000.0
CY2019Q2	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	5000000.0
CY2022Q2	us-gaap	Payments For Loans PaymentsForLoans	700000
CY2023Q2	opgn	Aggrement Amount Paid AggrementAmountPaid	1000000
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	2000000.0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	684498	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1301796	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1348974	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	6999000	shares
CY2024Q2	opgn	Preferred Stock Share Undesignated PreferredStockShareUndesignated	6999000	shares
CY2023Q1	opgn	Exercise Price Of Common Warrants ExercisePriceOfCommonWarrants	26.50
CY2023Q1	opgn	Exercise Price Of Pre Funded Warrants ExercisePriceOfPreFundedWarrants	0.10
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.785
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60500	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q2	opgn	Prefunded Warrants In Shares PrefundedWarrantsInShares	389083	shares
CY2023Q2	opgn	Common Warrants Issued CommonWarrantsIssued	449583	shares
CY2023Q2	opgn	Price Per Share Of Common Stock And Accompanying Common Warrant PricePerShareOfCommonStockAndAccompanyingCommonWarrant	7.785
CY2023Q2	opgn	Price Per Share Of Prefunded Warrant And Common Warrant PricePerShareOfPrefundedWarrantAndCommonWarrant	7.685
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	3000000.0	usd
CY2024Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	11099253	usd
CY2023Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10873867	usd
CY2017Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.04	pure
CY2019Q2	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	5000000.0
CY2019Q2	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	5000000.0
CY2022Q2	us-gaap	Payments For Loans PaymentsForLoans	700000
CY2023Q2	opgn	Aggrement Amount Paid AggrementAmountPaid	1000000
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	2000000.0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	684498	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1301796	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	6999000	shares
CY2023Q1	opgn	Exercise Price Of Common Warrants ExercisePriceOfCommonWarrants	26.50
CY2023Q1	opgn	Exercise Price Of Pre Funded Warrants ExercisePriceOfPreFundedWarrants	0.10
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.785
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60500	shares
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q2	opgn	Common Warrants Issued CommonWarrantsIssued	449583	shares
CY2023Q2	opgn	Price Per Share Of Common Stock And Accompanying Common Warrant PricePerShareOfCommonStockAndAccompanyingCommonWarrant	7.785
CY2023Q2	opgn	Price Per Share Of Prefunded Warrant And Common Warrant PricePerShareOfPrefundedWarrantAndCommonWarrant	7.685
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	3000000.0	usd
CY2023Q2	opgn	Exercise Price Of Common Warrants ExercisePriceOfCommonWarrants	7.785
CY2023Q2	opgn	Number Of Repriced Warrants To Purchase Shares NumberOfRepricedWarrantsToPurchaseShares	639691	shares
CY2024Q1	opgn	Additional Paid Capital AdditionalPaidCapital	300000	usd
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2023Q4	opgn	Shares Of Series D Preferred Stock For Sale SharesOfSeriesDPreferredStockForSale	1000
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Share Price SharePrice	4.09
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	opgn	Warrants Available For Inducement In Shares WarrantsAvailableForInducementInShares	1089274	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1	pure
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2024Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	11099253	usd
CY2023Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	10873867	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	11099253	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10873867	usd
CY2017Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.04	pure
CY2019Q2	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	5000000.0
CY2019Q2	us-gaap	Line Of Credit Facility Increase Decrease For Period Net LineOfCreditFacilityIncreaseDecreaseForPeriodNet	5000000.0
CY2022Q2	us-gaap	Payments For Loans PaymentsForLoans	700000
CY2023Q2	opgn	Aggrement Amount Paid AggrementAmountPaid	1000000
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	2000000.0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	8000000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	684498	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1079	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1301796	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	6999000	shares
CY2023Q1	opgn	Exercise Price Of Pre Funded Warrants ExercisePriceOfPreFundedWarrants	0.10
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.785
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60500	shares
CY2023Q2	opgn	Common Warrants Issued CommonWarrantsIssued	449583	shares
CY2023Q2	opgn	Price Per Share Of Common Stock And Accompanying Common Warrant PricePerShareOfCommonStockAndAccompanyingCommonWarrant	7.785
CY2023Q2	opgn	Price Per Share Of Prefunded Warrant And Common Warrant PricePerShareOfPrefundedWarrantAndCommonWarrant	7.685
CY2023Q2	opgn	Gross Proceeds From Equity Transaction GrossProceedsFromEquityTransaction	3500000	usd
CY2023Q2	opgn	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	3000000.0	usd
CY2023Q2	opgn	Exercise Price Of Common Warrants ExercisePriceOfCommonWarrants	7.785
CY2023Q2	opgn	Number Of Repriced Warrants To Purchase Shares NumberOfRepricedWarrantsToPurchaseShares	639691	shares
CY2024Q1	opgn	Additional Paid Capital AdditionalPaidCapital	300000	usd
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2023Q4	opgn	Shares Of Series D Preferred Stock For Sale SharesOfSeriesDPreferredStockForSale	1000
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Share Price SharePrice	4.09
CY2023Q4	opgn	Affiliates Holding Percentage AffiliatesHoldingPercentage	0.1999	pure
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	opgn	Warrants Available For Inducement In Shares WarrantsAvailableForInducementInShares	1089274	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.785
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1	pure
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2023Q2	opgn	Exercise Price Of Common Warrants ExercisePriceOfCommonWarrants	7.785
CY2023Q2	opgn	Number Of Repriced Warrants To Purchase Shares NumberOfRepricedWarrantsToPurchaseShares	639691	shares
CY2024Q1	opgn	Additional Paid Capital AdditionalPaidCapital	300000	usd
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2023Q4	opgn	Shares Of Series D Preferred Stock For Sale SharesOfSeriesDPreferredStockForSale	1000
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	us-gaap	Share Price SharePrice	4.09
CY2023Q4	opgn	Affiliates Holding Percentage AffiliatesHoldingPercentage	0.1999	pure
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.01
CY2023Q4	opgn	Warrants Available For Inducement In Shares WarrantsAvailableForInducementInShares	1089274	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.785
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1	pure
CY2023Q4	opgn	Number Of Warrants Exercised In Shares NumberOfWarrantsExercisedInShares	200000	shares
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2024Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	368391	usd
CY2023Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	156529	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	556628	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	367651	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2693	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2781	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4163	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4163	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	839302	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	138	usd
CY2024Q2	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	839302	usd
CY2023Q4	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	138	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	160480	usd
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2024Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	368391	usd
CY2023Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	156529	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	556628	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	367651	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2693	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2781	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4163	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4163	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	839302	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	138	usd
CY2024Q2	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	839302	usd
CY2023Q4	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	138	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	160480	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	280	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1938571	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2021616	usd
CY2024Q2	opgn	Lease Liability LeaseLiability	2099051	usd
CY2023Q4	opgn	Lease Liability LeaseLiability	2169839	usd
CY2023Q4	opgn	Gross Proceeds For Warrant Inducement GrossProceedsForWarrantInducement	2057000.000	usd
CY2024Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	368391	usd
CY2023Q2	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	156529	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	556628	usd
	opgn	Allocated Share Based Compensation Expense Benefit AllocatedShareBasedCompensationExpenseBenefit	367651	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2693	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2781	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4163	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4163	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1095517	shares
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	839302	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	138	usd
CY2024Q2	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	839302	usd
CY2023Q4	opgn	Lease Right Of Use Asset LeaseRightOfUseAsset	138	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	147943	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	280	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2021616	usd
CY2024Q2	opgn	Lease Liability LeaseLiability	2099051	usd
CY2023Q4	opgn	Lease Liability LeaseLiability	2169839	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	147943	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	280	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1938571	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2021616	usd
CY2024Q2	opgn	Lease Liability LeaseLiability	2099051	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	378279	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	388682	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	399388	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1338300	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3053618	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	954567	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2099051	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	58496	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	172344	usd
	us-gaap	Lease Cost LeaseCost	117130	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	116992	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	309303	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	280	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	opgn	Operating Leases OperatingLeases	801321	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	180790	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	368179	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	378279	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	388682	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	399388	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1338300	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3053618	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	954567	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2099051	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	58496	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	172344	usd
	us-gaap	Lease Cost LeaseCost	117130	usd
	us-gaap	Lease Cost LeaseCost	310970	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	116992	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	309303	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	280	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	opgn	Operating Leases OperatingLeases	801321	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	180790	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	368179	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	378279	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	388682	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	399388	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1338300	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3053618	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	954567	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2099051	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	58496	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	172344	usd
	us-gaap	Lease Cost LeaseCost	117130	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	116992	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	309303	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	280	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1682	usd
	opgn	Operating Leases OperatingLeases	801321	usd
CY2024Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.796	pure
CY2024Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.796	pure
CY2024Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	0.796	pure

Files In Submission

Name	View Source	Status
opgn-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
opgeninc_10q_htm.xml	Edgar Link	completed
0001829126-24-005664-index-headers.html	Edgar Link	pending
0001829126-24-005664-index.html	Edgar Link	pending
0001829126-24-005664.txt	Edgar Link	pending
0001829126-24-005664-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opgeninc_10q.htm	Edgar Link	pending
opgeninc_ex31-1.htm	Edgar Link	pending
opgeninc_ex31-2.htm	Edgar Link	pending
opgeninc_ex32-1.htm	Edgar Link	pending
opgn-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
opgn-20240630_def.xml	Edgar Link	unprocessable
opgn-20240630_lab.xml	Edgar Link	unprocessable
opgn-20240630_pre.xml	Edgar Link	unprocessable
0001829126-24-005664-index-headers.html	Edgar Link	pending
0001829126-24-005664-index.html	Edgar Link	pending
0001829126-24-005664.txt	Edgar Link	pending
0001829126-24-005664-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opgeninc_10q.htm	Edgar Link	pending
opgeninc_ex31-1.htm	Edgar Link	pending
opgeninc_ex31-2.htm	Edgar Link	pending
opgeninc_ex32-1.htm	Edgar Link	pending
opgn-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
opgn-20240630_cal.xml	Edgar Link	unprocessable
opgn-20240630_def.xml	Edgar Link	unprocessable
opgn-20240630_lab.xml	Edgar Link	unprocessable
opgn-20240630_pre.xml	Edgar Link	unprocessable
opgeninc_10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPGN
OPGEN INC Stock $opgn

2024 Q2 Form 10-Q Financial Statement

#000182912624005664 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPGN OPGEN INC Stock $opgn

2024 Q2 Form 10-Q Financial Statement

#000182912624005664 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPGN
OPGEN INC Stock $opgn